LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article: Potential role of Bacillus Calmette-Guérin (BCG) vaccination in COVID-19 pandemic mortality: Epidemiological and Immunological aspects.

    Charoenlap, Suvanee / Piromsopa, Krerk / Charoenlap, Chris

    Asian Pacific journal of allergy and immunology

    2020  Volume 38, Issue 3, Page(s) 150–161

    Abstract: SARS-CoV-2 had already killed more than 400,000 patients around the world according to data on 7 June 2020. Bacillus Calmette-Guérin (BCG) vaccine is developed from live-attenuated Mycobacterium bovis, which is a microorganism found in a cow. Discovered ... ...

    Abstract SARS-CoV-2 had already killed more than 400,000 patients around the world according to data on 7 June 2020. Bacillus Calmette-Guérin (BCG) vaccine is developed from live-attenuated Mycobacterium bovis, which is a microorganism found in a cow. Discovered by Dr. Albert Calmette and Camille Guérin since 1921, the BCG has served as a protection against tuberculosis and its complications. It is noticeable that countries which use mandatory BCG vaccination approach had lower COVID-19 infection and death rate. Current review aims to clarify this issue through epidemiological illustration of correlation between national BCG immunization and COVID-19 mortality, in addition to biological background of BCG-induced immunity Epidemiological data shows that universal BCG policy countries have lower median mortality rate compare to countries with past universal BCG policy and non-mass immunization BCG. (18 May 2020). Still, the links between BCG vaccination and better COVID-19 situation in certain countries are unclear, and more data on actual infection rate using SAR-CoV-2 antibody testing in large population sample is crucial for disease spreading comparison. Two immunological mechanisms, heterologous effects of adaptive immunity and trained innate immunity which induced by BCG vaccination, may explain host tolerance against COVID-19 infection, however, there is no direct evidence to support this biological background. Clinical trials related to BCG vaccination against COVID-19 are under investigation. Without a strong evidence, BCG must not be recommended for COVID-19 prevention, although, this should not be absolute contraindication. Risk of local and systemic complications from the vaccine should be informed to individual, who request BCG immunization.
    MeSH term(s) Adaptive Immunity ; BCG Vaccine/administration & dosage ; BCG Vaccine/adverse effects ; BCG Vaccine/immunology ; Betacoronavirus/immunology ; COVID-19 ; COVID-19 Vaccines ; Cause of Death ; Coronavirus Infections/immunology ; Coronavirus Infections/mortality ; Coronavirus Infections/prevention & control ; Coronavirus Infections/virology ; Host-Pathogen Interactions ; Humans ; Immunity, Innate ; Pandemics/prevention & control ; Pneumonia, Viral/immunology ; Pneumonia, Viral/mortality ; Pneumonia, Viral/prevention & control ; Pneumonia, Viral/virology ; SARS-CoV-2 ; Treatment Outcome ; Vaccination/adverse effects ; Viral Vaccines/administration & dosage ; Viral Vaccines/adverse effects ; Viral Vaccines/immunology
    Chemical Substances BCG Vaccine ; COVID-19 Vaccines ; Viral Vaccines
    Keywords covid19
    Language English
    Publishing date 2020-08-10
    Publishing country Thailand
    Document type Journal Article ; Review
    ZDB-ID 605782-2
    ISSN 2228-8694 ; 0125-877X
    ISSN (online) 2228-8694
    ISSN 0125-877X
    DOI 10.12932/AP-310520-0863
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Potential role of Bacillus Calmette-Guérin (BCG) vaccination in COVID-19 pandemic mortality: Epidemiological and Immunological aspects

    Charoenlap, Suvanee / Piromsopa, Krerk / Charoenlap, Chris

    Asian Pac J Allergy Immunol

    Abstract: SARS-CoV-2 had already killed more than 400,000 patients around the world according to data on 7 June 2020. Bacillus Calmette-Guérin (BCG) vaccine is developed from live-attenuated Mycobacterium bovis, which is a microorganism found in a cow. Discovered ... ...

    Abstract SARS-CoV-2 had already killed more than 400,000 patients around the world according to data on 7 June 2020. Bacillus Calmette-Guérin (BCG) vaccine is developed from live-attenuated Mycobacterium bovis, which is a microorganism found in a cow. Discovered by Dr. Albert Calmette and Camille Guérin since 1921, the BCG has served as a protection against tuberculosis and its complications. It is noticeable that countries which use mandatory BCG vaccination approach had lower COVID-19 infection and death rate. Current review aims to clarify this issue through epidemiological illustration of correlation between national BCG immunization and COVID-19 mortality, in addition to biological background of BCG-induced immunity Epidemiological data shows that universal BCG policy countries have lower median mortality rate compare to countries with past universal BCG policy and non-mass immunization BCG. (18 May 2020). Still, the links between BCG vaccination and better COVID-19 situation in certain countries are unclear, and more data on actual infection rate using SAR-CoV-2 antibody testing in large population sample is crucial for disease spreading comparison. Two immunological mechanisms, heterologous effects of adaptive immunity and trained innate immunity which induced by BCG vaccination, may explain host tolerance against COVID-19 infection, however, there is no direct evidence to support this biological background. Clinical trials related to BCG vaccination against COVID-19 are under investigation. Without a strong evidence, BCG must not be recommended for COVID-19 prevention, although, this should not be absolute contraindication. Risk of local and systemic complications from the vaccine should be informed to individual, who request BCG immunization.
    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #663128
    Database COVID19

    Kategorien

  3. Article ; Online: Effects of secondhand smoke exposure on asthma morbidity and health care utilization in children: a systematic review and meta-analysis.

    Wang, Zhen / May, Sara M / Charoenlap, Suvanee / Pyle, Regan / Ott, Nancy L / Mohammed, Khaled / Joshi, Avni Y

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology

    2015  Volume 115, Issue 5, Page(s) 396–401.e2

    Abstract: Background: Secondhand smoke (SHS) exposure can trigger asthma exacerbations in children. Different studies have linked increased asthma symptoms, health care use, and deaths in children exposed to SHS, but the risk has not been quantified uniformly ... ...

    Abstract Background: Secondhand smoke (SHS) exposure can trigger asthma exacerbations in children. Different studies have linked increased asthma symptoms, health care use, and deaths in children exposed to SHS, but the risk has not been quantified uniformly across studies.
    Objective: To perform a systematic review and meta-analysis to evaluate and quantify asthma severity and health care use from SHS exposure in children.
    Methods: A systematic review was undertaken to assess the association between asthma severity and SHS in children. Inclusion criteria included studies that evaluated children with SHS exposure and reported outcomes of interest with asthma severity including exacerbations. Random effect models were used to combine the outcomes of interest (hospitalization, emergency department or urgent care visits, severe asthma symptoms, wheeze symptoms, and pulmonary function test results) from the included studies.
    Results: A total of 1,945 studies were identified and 25 studies met the inclusion criteria. Children with asthma and SHS exposure were twice as likely to be hospitalized for asthma (odds ratio [OR] 1.85, 95% confidence interval [CI] 1.20-2.86, P = .01) than children with asthma but without SHS exposure. SHS exposure also was significantly associated with emergency department or urgent care visits (OR 1.66, 95% CI 1.02-2.69, P = 0.04), wheeze symptoms (OR 1.32, 95% CI 1.24, 1.41, P < .001), and lower ratio of forced expiratory volume in 1 second to forced vital capacity (OR -3.34, 95% CI -5.35 to -1.33, P = .001).
    Conclusion: Children with asthma and SHS exposure are nearly twice as likely to be hospitalized with asthma exacerbation and are more likely to have lower pulmonary function test results.
    MeSH term(s) Adolescent ; Asthma/epidemiology ; Asthma/etiology ; Child ; Child, Preschool ; Emergency Service, Hospital ; Female ; Forced Expiratory Volume/physiology ; Hospitalization ; Humans ; Infant ; Male ; Morbidity ; Patient Acceptance of Health Care ; Risk Factors ; Severity of Illness Index ; Tobacco Smoke Pollution/adverse effects
    Chemical Substances Tobacco Smoke Pollution
    Language English
    Publishing date 2015-11
    Publishing country United States
    Document type Journal Article ; Meta-Analysis
    ZDB-ID 1228189-x
    ISSN 1534-4436 ; 0003-4738 ; 1081-1206
    ISSN (online) 1534-4436
    ISSN 0003-4738 ; 1081-1206
    DOI 10.1016/j.anai.2015.08.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top